Top

Current Treatment Options in Gastroenterology

Published in:

01-03-2018 | Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Updates on Women’s Health Issues in Patients with Inflammatory Bowel Disease

Authors: Nirupama Bonthala, MD, Sunanda Kane, MD, MSPH

Published in: Current Treatment Options in Gastroenterology | Issue 1/2018

Abstract

Purpose of review

Inflammatory bowel disease affects approximately 800,000 women in the USA with the peak incidence between ages 15 to 40. Thus for many females, IBD can impact nearly every stage of their life from menarche to pregnancy, menopause, and beyond. This paper will review the most recent updates on the topics of sexual health, cervical cancer screening, menstruation, fertility, contraception, and menopause.

Recent findings

Menarche can be delayed in females especially those who are underweight, malnourished, or with active inflammatory bowel disease. Cyclical GI symptoms during a menstrual cycle are very common in women with IBD and should not be confused with flares. Overall fertility is similar to the general population unless females with IBD have had significant abdominal surgery but reassuringly this infertility appears to be restored with the use of in vitro fertilization. Discussion regarding family planning is imperative in women with IBD with a strong recommendation to consider long-acting highly effective contraceptives such as intrauterine devices or implants. Cervical cancer screening should be tailored in women on immunosuppressive medications and all women under 26 years of age should be advised to receive the human papilloma virus vaccination.

Summary

As gastroenterologists will have longitudinal relationships with their female IBD patients, they must be knowledgeable about sex-specific issues during each stage of life from puberty to after menopause to optimize their patient’s care.

• Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857. This article provides the most up to date incidence and prevalence of UC and IBD.–63. https://doi.org/10.1016/j.cgh.2016.10.039.CrossRefPubMed

Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. https://doi.org/10.1053/j.gastro.2011.10.001.CrossRefPubMed

Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008;14:S4–5. https://doi.org/10.1002/ibd.20545.CrossRefPubMed

Ballinger B, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res. 2003;53(2):205–10. https://doi.org/10.1203/00006450-200302000-00002.CrossRefPubMed

Ferguson A, Sedgwick DM. Juvenile onset in inflammatory bowel disease: height and body mass index in adult life. Br Med J. 1994;308(6939):1259–63. https://doi.org/10.1136/bmj.308.6939.1259.CrossRef

Brain CE, Savage MO. Growth and puberty in chronic in inflammatory bowel disease. Baillie’re’s clinical Gastroenterology. 1994;8(1):83–100.CrossRefPubMed

Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(6):839–49. https://doi.org/10.1002/ibd.20378.CrossRefPubMed

Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual cycle? Br J Obstet Gynaecol. 1998;105(12):1322–5. https://doi.org/10.1111/j.1471-0528.1998.tb10014.x.CrossRefPubMed

• Bharadwaj S, Kulkarni G, Shen B. Menstrual cycle, sex hormones in female inflammatory bowel disease patients with and without surgery. J Dig Dis. 2015;16(5):245–55. This article discussed cyclical GI symptoms with menstrual cycle. https://doi.org/10.1111/1751-2980.12247.CrossRefPubMed

10.

Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93(10):1867–72. https://doi.org/10.1111/j.1572-0241.1998.540_i.x.CrossRefPubMed

11.

Parlak E, Dağli U, Alkim C, Dişibeyaz S, Tunç B, Ulker A, et al. Pattern of gastrointestinal and psychosomatic symptoms across the menstrual cycle in women with inflammatory bowel disease. Turk J Gastroenterol. 2003;14(4):250–6.

12.

• Gawron LM, Goldberger A, Gawron AJ, Hammond C, Keefer L. The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20(10):1729–33. Improvement in cyclical IBD symptoms was reported in 19% of women using estrogen-based therapy and 47% of women using a levonorgestrel intrauterine device. https://doi.org/10.1097/MIB.0000000000000134.CrossRefPubMed

13.

• Saha S, Zhao YQ, Shah SA, Esposti SD, Lidofsky S, Salih S, et al. Menstrual cycle changes in women with in inflammatory bowel disease: a study from the ocean state Crohn’s and colitis area registry. Inflamm Bowel Dis. 2014;20(3):534–40. Up to 25% of females experienced changes in their menstrual cycle the year prior to their diagnosis of IBD. https://doi.org/10.1097/01.MIB.0000441347.94451.cf.

14.

Lim SM, Nam CM, Kimetal YN. The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. Gut and Liver. 2013;7(1):51–7. https://doi.org/10.5009/gnl.2013.7.1.51.CrossRefPubMedPubMedCentral

15.

Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–9. https://doi.org/10.1016/j.cgh.2007.07.012.CrossRefPubMed

16.

Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15(5):720–5. https://doi.org/10.1002/ibd.20839.CrossRefPubMed

17.

Sellinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7(6):206–13.CrossRef

18.

Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(5):591–9. https://doi.org/10.1002/ibd.20082.CrossRefPubMed

19.

Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55(8):1198–206. https://doi.org/10.1136/gut.2005.078097.CrossRefPubMedPubMedCentral

20.

Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):847–53. https://doi.org/10.1111/apt.12478.CrossRefPubMed

21.

Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21(6):469–74. https://doi.org/10.1136/gut.21.6.469.CrossRefPubMedPubMedCentral

22.

Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NAG. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58(2):229–37. https://doi.org/10.1016/S0020-7292(97)00088-X.CrossRefPubMed

23.

Fréour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O, et al. Ovarian reserve in young women of reproductive age with Crohn's disease. Inflamm Bowel Dis. 2012;18(8):1515–22. https://doi.org/10.1002/ibd.21872.

24.

Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon rectum. 2007;50(8):1128–38. https://doi.org/10.1007/s10350-007-0240-7.

25.

Bharadwaj S, Philpott JR, Barber MD, Graff l, Shen B. Women’s health issues after ileal pouch surgery. Inflamm Bowel Dis. 2014;20(12):2470–82. https://doi.org/10.1097/MIB.0000000000000171.CrossRefPubMed

26.

• Pabby V, Oza SS, Dodge LE, Hacker MR, Moragianni VA, Correia K, et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastamosis. Am J Gastroenterol. 2015;110(6):792–7. This study demonstrated that live birth rates after IVF in women with IPAAs were comparable to women with UC without IPAA and women without UC. https://doi.org/10.1038/ajg.2014.400.

27.

Heetun ZS, Byrnes C, Neary P, et al. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26(4):513–33. https://doi.org/10.1111/j.1365-2036.2007.03397.x.CrossRefPubMed

28.

Zelissen PM, van Hattum J, Poen H, et al. Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scand J Gastroenterol. 1988;23(9):1100–4. https://doi.org/10.3109/00365528809090175.CrossRefPubMed

29.

O'Moráin C, Smethurst P, Doré CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25(10):1078–84. https://doi.org/10.1136/gut.25.10.1078.CrossRefPubMedPubMedCentral

30.

Levi AJ, Fisher AM, Hughes L, Hendry WF. Male infertility due to sulphasalazine. Lancet. 1979;2(8137):276–8.CrossRefPubMed

31.

Grosen A, Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB. The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure. Inflamm Bowel Dis. 2017;23(4):561–9. https://doi.org/10.1097/MIB.0000000000001064.CrossRefPubMed

32.

Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):849–77. https://doi.org/10.1016/j.bpg.2007.06.002.CrossRefPubMed

33.

Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9–17. https://doi.org/10.1053/gast.2003.50014.CrossRefPubMed

34.

• Gawron LM, Gawron AJ, Kasper A, Hammond C, Keefer L. Contraceptive method selection by women with inflammatory bowel diseases: a cross-sectional survey. Contraception. 2014;89(5):419–25. This survey study revealed that 23% of women with IBD who were at risk for pregnancy did not use any form of contraception and that only 17% used highly effective methods such as an intrauterine device. https://doi.org/10.1016/j.contraception.2013.12.016.CrossRefPubMedPubMedCentral

35.

•• Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1. Long term reversible contraception and progestin only contraceptives are the preferred method of contraception in women with IBD

36.

Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM. Contraceptive use among women with inflammatory bowel disease: a systematic review. Contraception. 2010;82(1):72–85. https://doi.org/10.1016/j.contraception.2010.02.012.CrossRefPubMed

37.

• Gawron LM, Goldberger A, Gawron AJ, Hammond C, Keefer L. The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20(10):1729–33. Nearly 20% of women with IBD reported improved GI symptoms related to menses while on OCPs. https://doi.org/10.1097/MIB.0000000000000134.CrossRefPubMed

38.

Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(2 Pt 1):380–9. https://doi.org/10.1097/AOG.0b013e3182994c43.

39.

Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(10):953–62. https://doi.org/10.1111/apt.12294.

40.

Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(9):2272–80. https://doi.org/10.1111/j.1572-0241.2008.02052.x.CrossRefPubMed

41.

• Cotton CC, Baird D, Sandler RS, Long MD. Hormonal contraception use is common among patients with inflammatory bowel diseases and elevated risk for deep vein thrombosis. Inflamm Bowel Dis. 2016;22(7):1631–8. Nearly one third of women surveyed were on hormonal contraception even despite elevated risk of deep vein thrombosis. https://doi.org/10.1097/MIB.0000000000000800.CrossRefPubMedPubMedCentral

42.

Timmer A, Sutherland LR, Martin F. The Canadian Mesalamine for remission of Crohn’s disease study group. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. Gastroenterology. 1998;114(6):1143–50. https://doi.org/10.1016/S0016-5085(98)70419-6.CrossRefPubMed

43.

Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut. 1999;45(2):218–22. https://doi.org/10.1136/gut.45.2.218.CrossRefPubMedPubMedCentral

44.

Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of oral contraceptive use on reoperation following surgery for Crohn’s disease. Dig Dis Sci. 1992;37(9):1377–82. https://doi.org/10.1007/BF01296007.CrossRefPubMed

45.

Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20. https://doi.org/10.1053/gast.2001.20912.

46.

Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400. https://doi.org/10.1111/j.1572-0241.2008.02064.x.CrossRefPubMed

47.

• Ortizo R, Lee SY, Nguyen, et al. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017;29(9):1064–70. This meta-analysis of 20 studies showed an increased risk of 30% for the development of UC and an increased risk of 24% for the development of CD in those who were exposed to OCPs. https://doi.org/10.1097/MEG.0000000000000915.CrossRefPubMed

48.

Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73(5):470–87. https://doi.org/10.1016/j.contraception.2005.12.010.CrossRefPubMed

49.

Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599–604. https://doi.org/10.1016/j.amjmed.2009.01.022.CrossRefPubMedPubMedCentral

50.

Wakeman J. Exacerbation of Crohn’s disease after insertion of a levonorgestrel intrauterine system: a case report. J Fam Plann Reprod Health Care. 2003;29(3):154. https://doi.org/10.1783/147118903101197548.CrossRefPubMed

51.

Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK family planning and reproductive health research network: 5-year report. J Fam Plann Reprod Health Care. 2002;28(2):73–7. https://doi.org/10.1783/147118902101196225.CrossRefPubMed

52.

• Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015;99(3):521534. This study reviewed demographics of menopause in women with IBD.CrossRef

53.

Lichtarowicz A, Norman C, Calcraft B, Morris JS, Rhodes J, Mayberry J. A study of the menopause, smoking, and contraception in women with Crohn's disease. Q J Med. 1989;72(267):623–31.PubMed

54.

Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1193–6. https://doi.org/10.1111/j.1572-0241.2007.01700.x.CrossRefPubMed

55.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc. 2002;288(3):321–33.

56.

Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Hormone therapy increases risk of ulcerative colitis but not Crohn’s disease. Gastroenterology. 2012;43(5):1199–206.CrossRef

57.

Timmer A, Bauer A, Dignass A, Rogler G. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol. 2007;5(1):87–94. https://doi.org/10.1016/j.cgh.2006.10.018.CrossRefPubMed

58.

Metcalf A, Dozois R, Kelly A. Sexual function in women after proctocolectomy. Ann Surg. 1986;204(6):624–7. https://doi.org/10.1097/00000658-198612000-00002.CrossRefPubMedPubMedCentral

59.

Weerakoon P. Sexuality and the patient with a stoma. Sex Disabil. 2001;19(2):121–9. https://doi.org/10.1023/A:1010625806500.CrossRef

60.

Muller KR, Prosser R, Bampton P, Mountifield R, Andrews JM. Female gender and surgery impair relationships, body image, and sexuality in inflammatory bowel disease: patient perceptions. Inflamm Bowel Dis. 2010;16(4):657–63. https://doi.org/10.1002/ibd.21090.CrossRefPubMed

61.

Borum ML, Igiehon E, Shafa S. Physicians may inadequately address sexuality in women with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(2):181. https://doi.org/10.1002/ibd.20955.CrossRefPubMed

62.

Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women’s interagency HIV study group. J Acquir Immune Defic Syndr. 1999;21(1):33–41. https://doi.org/10.1097/00126334-199905010-00005.

63.

•• American College of Obstetricians and Gynecologists. ACOG guidelines for womens health care. Washington, DC: The College; 2014. Updated from 2010, this document provides guidance on a wide variety of womens health issues.

64.

Nguyen ML, Flowers L. Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin N Am. 2013 Jun;40(2):339–57. https://doi.org/10.1016/j.ogc.2013.02.005.CrossRef

65.

Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167–71. https://doi.org/10.3748/wjg.v12.i38.6167.

66.

Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–6. https://doi.org/10.1111/j.1572-0241.2007.01582.x.CrossRefPubMed

67.

De Sanjose S, Quint G, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. https://doi.org/10.1016/S1470-2045(10)70230-8.CrossRefPubMed

68.

Lees CW, Critchley J, Chee N, Beez T, Gailer RE, Williams AR, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009;15(11):1621–9. https://doi.org/10.1002/ibd.20959.

69.

Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451–8. https://doi.org/10.1053/j.gastro.2008.10.021.CrossRefPubMed

70.

• Rungoe C, Simonsen J, Riis L, Frisch M, Langholz E, Jess T. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13(4):693–700.e691. This is a population-based cohort of nearly 30,000 women with IBD which reported increased risk for cervical dysplasia in women with IBD and increased risk of cervical cancer in those with CD. https://doi.org/10.1016/j.cgh.2014.07.036.CrossRefPubMed

71.

• Pandey N, Herrera HH, Johnson CM, MacCarthy AA, Copeland l. Preventative Care for Patients with inflammatory bowel disease in the veterans health administration. Medicine. 2016;95(27):e4012. Retrospective study performed at the Veteran’s Health Administration showed that among women under 65 years of age with IBD, 15% had abnormal Pap smears compared to 5% among normal patient population. https://doi.org/10.1097/MD.0000000000004012.CrossRefPubMedPubMedCentral

72.

• Bulletins—Gynecology CoP. ACOG practice bulletin number 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):111–30. This practice bulletin provides the most recent guidance on cervical cancer screening.CrossRef

73.

Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15(9):1399–409. https://doi.org/10.1002/ibd.20944.CrossRefPubMed

74.

•• Farraye F, Melmed G, Lichtenstein R, et al. ACG clinical guideline: preventitive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58. This ACG clinical guidelines for preventitive care recommends yearly Pap smears in women who are on immunosupressive treatments. https://doi.org/10.1038/ajg.2016.537.CrossRefPubMed

75.

• Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2014;63:1–30. This guideline recommends HPV vaccination for females aged 9 to 26.

76.

Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536–40. https://doi.org/10.1002/ibd.21667.CrossRefPubMed

Title: Updates on Women’s Health Issues in Patients with Inflammatory Bowel Disease
Authors: Nirupama Bonthala, MD
Sunanda Kane, MD, MSPH
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 1/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-018-0172-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Update on Bowel Preparation for Colonoscopy

Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

Expanding Role of Third Space Endoscopy in the Management of Esophageal Diseases

Management of Serrated Polyps of the Colon

Endoscopic Treatments of GERD

The Natural History of IBD: Lessons Learned

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage